International audienceBackground: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diagnosis of Alzheimer’s disease (AD) in research and clinical settings. We previously described the PLM-scale (Paris-Lille-Montpellier study), which combines Aβ42, tau, and phosphorylated ptau(181) biomarkers in an easy to use and clinically relevant way. The purpose of this work is to evaluate an optimized PLMR-scale (PLM ratio scale) that now includes the Aβ42/Aβ40 ratio to detect AD versus non-AD (NAD) participants in clinical routine of memory centers.Methods: Both scales were compared using 904 participants with cognitive impairment recruited from two independent cohorts (Mtp-1 and Mtp-2). The CSF Aβ42/Aβ40 ratio was meas...
Background:To enhance the accuracy of clinical diagnosis for Alzheimer’s disease (AD), pre-mortem bi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceBackground: Cerebrospinal fluid (CSF) biomarkers have recently been included i...
Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diagnos...
<p>Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diag...
Introduction: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p...
In the last decades, an important role of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease...
OBJECTIVE: The diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (...
INTRODUCTION: The relevance of the cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheim...
Abstract The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Ta...
peer reviewedBACKGROUND: The incoming disease-modifying therapies against Alzheimer's disease (AD) r...
Abstract Background Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of ...
Background: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD)...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceThe cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ...
Background:To enhance the accuracy of clinical diagnosis for Alzheimer’s disease (AD), pre-mortem bi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceBackground: Cerebrospinal fluid (CSF) biomarkers have recently been included i...
Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diagnos...
<p>Background: Cerebrospinal fluid (CSF) biomarkers (Aβ peptides and tau proteins) improved the diag...
Introduction: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p...
In the last decades, an important role of cerebrospinal fluid (CSF) biomarkers for Alzheimer disease...
OBJECTIVE: The diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (...
INTRODUCTION: The relevance of the cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheim...
Abstract The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Ta...
peer reviewedBACKGROUND: The incoming disease-modifying therapies against Alzheimer's disease (AD) r...
Abstract Background Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence of ...
Background: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD)...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceThe cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ...
Background:To enhance the accuracy of clinical diagnosis for Alzheimer’s disease (AD), pre-mortem bi...
Background/Aims: Disease-modifying therapy for Alzheimer’s disease (AD) has led to a need for biomar...
International audienceBackground: Cerebrospinal fluid (CSF) biomarkers have recently been included i...